Cargando…
Evolution of Diploid Progenitor Lung Cell Applications: From Optimized Biotechnological Substrates to Potential Active Pharmaceutical Ingredients in Respiratory Tract Regenerative Medicine
The objective of this review is to describe the evolution of lung tissue-derived diploid progenitor cell applications, ranging from historical biotechnological substrate functions for vaccine production and testing to current investigations around potential therapeutic use in respiratory tract regen...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533713/ https://www.ncbi.nlm.nih.gov/pubmed/34685505 http://dx.doi.org/10.3390/cells10102526 |
_version_ | 1784587379854540800 |
---|---|
author | Laurent, Alexis Abdel-Sayed, Philippe Hirt-Burri, Nathalie Scaletta, Corinne Michetti, Murielle de Buys Roessingh, Anthony Raffoul, Wassim Applegate, Lee Ann |
author_facet | Laurent, Alexis Abdel-Sayed, Philippe Hirt-Burri, Nathalie Scaletta, Corinne Michetti, Murielle de Buys Roessingh, Anthony Raffoul, Wassim Applegate, Lee Ann |
author_sort | Laurent, Alexis |
collection | PubMed |
description | The objective of this review is to describe the evolution of lung tissue-derived diploid progenitor cell applications, ranging from historical biotechnological substrate functions for vaccine production and testing to current investigations around potential therapeutic use in respiratory tract regenerative medicine. Such cell types (e.g., MRC-5 or WI-38 sources) were extensively studied since the 1960s and have been continuously used over five decades as safe and sustainable industrial vaccine substrates. Recent research and development efforts around diploid progenitor lung cells (e.g., FE002-Lu or Walvax-2 sources) consist in qualification for potential use as optimal and renewed vaccine production substrates and, alternatively, for potential therapeutic applications in respiratory tract regenerative medicine. Potentially effective, safe, and sustainable cell therapy approaches for the management of inflammatory lung diseases or affections and related symptoms (e.g., COVID-19 patients and burn patient severe inhalation syndrome) using local homologous allogeneic cell-based or cell-derived product administrations are considered. Overall, lung tissue-derived progenitor cells isolated and produced under good manufacturing practices (GMP) may be used with high versatility. They can either act as key industrial platforms optimally conforming to specific pharmacopoeial requirements or as active pharmaceutical ingredients (API) for potentially effective promotion of lung tissue repair or regeneration. |
format | Online Article Text |
id | pubmed-8533713 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-85337132021-10-23 Evolution of Diploid Progenitor Lung Cell Applications: From Optimized Biotechnological Substrates to Potential Active Pharmaceutical Ingredients in Respiratory Tract Regenerative Medicine Laurent, Alexis Abdel-Sayed, Philippe Hirt-Burri, Nathalie Scaletta, Corinne Michetti, Murielle de Buys Roessingh, Anthony Raffoul, Wassim Applegate, Lee Ann Cells Review The objective of this review is to describe the evolution of lung tissue-derived diploid progenitor cell applications, ranging from historical biotechnological substrate functions for vaccine production and testing to current investigations around potential therapeutic use in respiratory tract regenerative medicine. Such cell types (e.g., MRC-5 or WI-38 sources) were extensively studied since the 1960s and have been continuously used over five decades as safe and sustainable industrial vaccine substrates. Recent research and development efforts around diploid progenitor lung cells (e.g., FE002-Lu or Walvax-2 sources) consist in qualification for potential use as optimal and renewed vaccine production substrates and, alternatively, for potential therapeutic applications in respiratory tract regenerative medicine. Potentially effective, safe, and sustainable cell therapy approaches for the management of inflammatory lung diseases or affections and related symptoms (e.g., COVID-19 patients and burn patient severe inhalation syndrome) using local homologous allogeneic cell-based or cell-derived product administrations are considered. Overall, lung tissue-derived progenitor cells isolated and produced under good manufacturing practices (GMP) may be used with high versatility. They can either act as key industrial platforms optimally conforming to specific pharmacopoeial requirements or as active pharmaceutical ingredients (API) for potentially effective promotion of lung tissue repair or regeneration. MDPI 2021-09-24 /pmc/articles/PMC8533713/ /pubmed/34685505 http://dx.doi.org/10.3390/cells10102526 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Laurent, Alexis Abdel-Sayed, Philippe Hirt-Burri, Nathalie Scaletta, Corinne Michetti, Murielle de Buys Roessingh, Anthony Raffoul, Wassim Applegate, Lee Ann Evolution of Diploid Progenitor Lung Cell Applications: From Optimized Biotechnological Substrates to Potential Active Pharmaceutical Ingredients in Respiratory Tract Regenerative Medicine |
title | Evolution of Diploid Progenitor Lung Cell Applications: From Optimized Biotechnological Substrates to Potential Active Pharmaceutical Ingredients in Respiratory Tract Regenerative Medicine |
title_full | Evolution of Diploid Progenitor Lung Cell Applications: From Optimized Biotechnological Substrates to Potential Active Pharmaceutical Ingredients in Respiratory Tract Regenerative Medicine |
title_fullStr | Evolution of Diploid Progenitor Lung Cell Applications: From Optimized Biotechnological Substrates to Potential Active Pharmaceutical Ingredients in Respiratory Tract Regenerative Medicine |
title_full_unstemmed | Evolution of Diploid Progenitor Lung Cell Applications: From Optimized Biotechnological Substrates to Potential Active Pharmaceutical Ingredients in Respiratory Tract Regenerative Medicine |
title_short | Evolution of Diploid Progenitor Lung Cell Applications: From Optimized Biotechnological Substrates to Potential Active Pharmaceutical Ingredients in Respiratory Tract Regenerative Medicine |
title_sort | evolution of diploid progenitor lung cell applications: from optimized biotechnological substrates to potential active pharmaceutical ingredients in respiratory tract regenerative medicine |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533713/ https://www.ncbi.nlm.nih.gov/pubmed/34685505 http://dx.doi.org/10.3390/cells10102526 |
work_keys_str_mv | AT laurentalexis evolutionofdiploidprogenitorlungcellapplicationsfromoptimizedbiotechnologicalsubstratestopotentialactivepharmaceuticalingredientsinrespiratorytractregenerativemedicine AT abdelsayedphilippe evolutionofdiploidprogenitorlungcellapplicationsfromoptimizedbiotechnologicalsubstratestopotentialactivepharmaceuticalingredientsinrespiratorytractregenerativemedicine AT hirtburrinathalie evolutionofdiploidprogenitorlungcellapplicationsfromoptimizedbiotechnologicalsubstratestopotentialactivepharmaceuticalingredientsinrespiratorytractregenerativemedicine AT scalettacorinne evolutionofdiploidprogenitorlungcellapplicationsfromoptimizedbiotechnologicalsubstratestopotentialactivepharmaceuticalingredientsinrespiratorytractregenerativemedicine AT michettimurielle evolutionofdiploidprogenitorlungcellapplicationsfromoptimizedbiotechnologicalsubstratestopotentialactivepharmaceuticalingredientsinrespiratorytractregenerativemedicine AT debuysroessinghanthony evolutionofdiploidprogenitorlungcellapplicationsfromoptimizedbiotechnologicalsubstratestopotentialactivepharmaceuticalingredientsinrespiratorytractregenerativemedicine AT raffoulwassim evolutionofdiploidprogenitorlungcellapplicationsfromoptimizedbiotechnologicalsubstratestopotentialactivepharmaceuticalingredientsinrespiratorytractregenerativemedicine AT applegateleeann evolutionofdiploidprogenitorlungcellapplicationsfromoptimizedbiotechnologicalsubstratestopotentialactivepharmaceuticalingredientsinrespiratorytractregenerativemedicine |